The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
The market for lateral flow immunoassay (LFIA) based rapid tests has shown consistent growth in recent years. Projections indicate it will expand from $7.17 billion in 2025 to $7.31 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 2.0%. Historically, this expansion is a result of the broadened scope of rapid infectious disease screening, greater uptake of pregnancy and fertility testing, the development of point-of-care diagnostics, the accessibility of affordable rapid tests, and an increase in public health screening programs.
The market for lateral flow immunoassay (LFIA) based rapid tests is projected to experience consistent expansion over the coming years. This market is anticipated to reach a valuation of $8.67 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the forecast period include greater investments in decentralized diagnostics, the widening scope of self-testing applications, a heightened need for swift cardiac and toxicology tests, increasing incorporation with digital health platforms, and an enhanced emphasis on early disease identification. Key trends anticipated in the same period involve a heightened demand for rapid immunoassay-based testing, the increasing uptake of home-use LFIA kits, an expanding utilization of multiplex detection assays, broader applications for infectious disease testing, and a stronger emphasis on designing user-friendly tests.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3293&type=smp
Which Growth Drivers Are Expected To Support The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Forward?
The growing occurrence of chronic diseases is projected to propel the expansion of the lateral flow immunoassay (LFIA) based rapid test market in the future. Chronic diseases, also recognized as non-communicable diseases (NCDs), are long-standing health conditions that often persist throughout a person’s lifetime. Lateral flow immunoassay (LFIA) based rapid tests offer benefits such as early diagnosis, point-of-care convenience, rapid outcomes, regular oversight, and help reduce healthcare costs involved in chronic disease care. LFIA-based rapid tests are highly regarded in the management of chronic diseases as they provide quick and accessible results, enabling patients and medical professionals to make timely choices concerning treatment and dietary adjustments. For instance, in June 2024, according to the National Health Service, a UK-based government department, 3,615,330 individuals registered with a general practitioner (GP) were diagnosed with non-diabetic hyperglycemia or pre-diabetes (a state with elevated blood sugar levels, not high enough to be classified as diabetes) in 2023, representing an 18% increase from 3,065,825 cases in 2022. Consequently, the rising prevalence of chronic diseases is serving as a significant driver for the growth of the lateral flow immunoassay (LFIA) based rapid test market.
What Are The Core Segment Classifications In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
The lateral flow immunoassay (lfia) based rapid test market covered in this report is segmented –
1) By Technique: Competitive Assay, Sandwich Assay, Multiplex Detection Assay
2) By Application: Infectious Disease, Pregnancy And Fertility, Toxicology, Cardiac Marker And Cholesterol Testing, Other Applications
3) By End-Users: Hospitals And Clinics, Diagnostic Laboratories, Home Care, Other End Users
Subsegments:
1) By Competitive Assay: Direct Competitive Assays, Indirect Competitive Assays
2) By Sandwich Assay: Single-step Sandwich Assays, Two-step Sandwich Assays
3) By Multiplex Detection Assay: Multi-analyte Assays, Simultaneous Detection Of Various Targets
Which Trends Are Shaping The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Landscape?
Leading companies in the lateral flow immunoassay (LFIA)-based rapid test market are concentrating on adopting technologies like Integrated Health Solutions to boost diagnostic effectiveness, streamline operational processes, and deliver extensive patient support through enhanced data sharing and collaboration across healthcare platforms. Integrated Health Solutions represent comprehensive healthcare systems that interconnect diverse services, technologies, and data to improve patient outcomes and optimize operations. For example, in June 2024, the Switzerland-based pharmaceutical company F. Hoffmann-La Roche AG introduced the analytical units for its Cobas Pro integrated solutions. The Cobas Pro system is capable of processing up to 1,000 samples per hour with its sample supply unit and features high-speed analytical units that can perform up to 900 tests per hour for the ISE (ion-selective electrode) and 1,000 tests per hour for the Cobas C 503 unit, which specializes in clinical chemistry.
Which Organizations Are Involved In The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
Major companies operating in the lateral flow immunoassay (lfia) based rapid test market are Abbott Laboratories, F. Hoffmann-La Roche, Quidel Corporation, Becton Dickinson and Company, Danaher Corporation, Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., PerkinElmer Inc., Hologic Inc., LTEK Co. Ltd., JOYSBIO Biotechnology, Jiangsu Medomics Medical Technologies, Diagnocure, Ubio Biotechnology Systems, Elabscience® Immunoassay Kits, FyoniBio / Glycotope GmbH, Atomo Diagnostics Limited, INDICAL Bioscience, Lionex Gmbh, BIOMED Labordiagnostik GmbH, EKF Diagnostics, Launch Diagnostics, Diagnostic Instruments Ltd, Qiagen N.V., Merck KGaA, 3a Diagnostics, Roche Holding AG, Biomaxima, SensDx, Vitrosens Biotechnology, Bioeasy Biotechnology, Fujirebio, Immunodiagnostic Systems Holdings PLC, Mesa Biotech Inc, CTK Biotech
Access The Complete Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report:
Which Region Commands The Largest Share Of The Lateral Flow Immunoassay (LFIA) Based Rapid Test Market?
North America was the largest region in the lateral flow immunoassay (LFIA) based rapid test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral flow immunoassay (lfia) based rapid test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access a Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report for Deeper Competitive Insights
Browse Through More Reports Similar to the Global Lateral Flow Immunoassay (LFIA) Based Rapid Test Market 2026, By The Business Research Company
Lateral Flow Assays Market Report 2026
https://www.thebusinessresearchcompany.com/report/lateral-flow-assays-global-market-report
Immunoassay Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunoassay-global-market-report
Immunodiagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/immunodiagnostics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model